Avicena Group, Inc.

57 articles about Avicena Group, Inc.

• Avicena Group, Inc.'s HD-02 to Proceed to National Institutes of Health (NIH) Sponsored Phase III Huntington's Disease Trial

  3/12/2008

• Avicena Group, Inc. Announces Positive Phase II Data for a Combination Trial Involving AL-08 for the Treatment of Amyotrophic Lateral Sclerosis

  12/3/2007

• Data on Avicena Group, Inc.'s Drug Candidate HD-02 Presented at the 2007 World Congress on Huntington's Disease

  11/19/2007

• USPTO Issues Patent for Avicena Group, Inc.'s Proprietary Compounds to Treat Amyotrophic Lateral Sclerosis Patent Expands Existing IP to Treat ALS

  11/13/2007

• Survival Data for Avicena Group, Inc.'s Amyotrophic Lateral Sclerosis Drug Candidate, AL-02, to be Presented at 18th International Symposium on ALS/MND

  10/18/2007

• Avicena Group, Inc. Appoints Dr. Belinda Tsao-Nivaggioli as Chairman of the Board of Directors

  10/11/2007

• Avicena Group, Inc. to Present at 4th Annual Biotechnology Industry Organization (BIO) InvestorForum Conference Expansion of Drug Pipeline and Advancement of Clinical Programs

  10/9/2007

• Avicena Group, Inc. Appoints Dr. M. Flint Beal to Board of Directors

  9/28/2007

• Avicena Group, Inc. Announces Closing of Private Offering

  9/26/2007

• Avicena Group, Inc. Reports Second Quarter 2007 Results

  9/4/2007

• Avicena Group, Inc. Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds

  8/28/2007

• Avicena Group, Inc. Scientific Collaborator Advances Program for Using Energy Enhancing Molecules to Treat Neuromuscular Diseases

  8/24/2007

• Avicena Group, Inc. to Present at Noble Financial Conference

  8/17/2007

• Avicena Group, Inc. to Be Featured on the Nationally Syndicated Television Series, Heartbeat of America, on July 20, 2007

  7/18/2007

• Avicena Group, Inc. to Proceed to Confirmatory Phase III Amyotrophic Lateral Sclerosis (ALS) Trial

  7/17/2007

• Avicena Group, Inc. Patient Enrollment on Target in National Institutes of Health (NIH) Phase III Parkinson's Disease Trial

  7/16/2007

• Avicena Group, Inc. to Advance Huntington's Disease Clinical Program into Phase III

  6/28/2007

• Avicena Group, Inc. to Present its Huntington's Disease Clinical Program at the Huntington's Disease of America Society 22nd Annual Convention

  6/15/2007

• Avicena Group, Inc.'s Proprietary Dermaceutical Compound to be Subject of Presentation at the Strategic Research Institute's 4th Annual Cosmeceuticals Conference

  6/11/2007

• Avicena Group, Inc. CEO Featured in Exclusive Interview With WallSt.net

  5/30/2007